Clinical Takeaway Children born to mothers who used cannabis during pregnancy showed a modestly elevated risk for autism spectrum disorder and a smaller increase in risk for ADHD, based on a meta-analysis...
Cannabis-based medicines for chronic neuropathic pain in adults.
Estimates of the population prevalence of chronic pain with neuropathic components range from 6% to 10%. Current pharmacological treatments for neuropathic p…
Endocannabinoid System Research: Cannabis for PTSD and SUD
Clinical Takeaway People with PTSD and co-occurring substance use disorders who use cannabis can still benefit meaningfully from trauma-focused treatments. Cannabis use does not appear to undermine the effectiveness of evidence-based PTSD...
Childhood Adversity Linked to Nearly Doubled Odds of Heart Attack in Adulthood
The pooled ORs for the magnitude of the relationship between ACEs and MI were OR=1.88; 95% CI, 1.40–2.53, before adjustment for CVD risk factors, and OR=1.78; 95% CI, 1.24–2.57, after adjustment for CVD risk factors. The association between ACEs and MI was OR=2.09; 95% CI, 1.43–3.06, after further adjustment for psychological factors.
CBD Probably Reduces Seizures in Refractory Epilepsy, But Raises Risk of Serious Adverse Events
Cannabidiol 20 mg/kg/day and 10 mg/kg/day probably increased the frequency of participants who achieved a ≥50% reduction in monthly seizures (20 mg/kg/day: RR 1.92; 95% CI 1.49–2.46; 10 mg/kg/day: RR 1.94; 95% CI 1.32–2.86, moderate certainty). The incidence of serious adverse events is probably increased with CBD 20 mg/kg/day (RR 2.30; 95% CI 1.36–3.89, moderate certainty).
Cannabis Does Not Consistently Change Sleep Architecture, Review Finds—But Withdrawal Does
Cannabis administration does not consistently alter sleep duration, latency, wake time, efficiency, or sleep staging. While early studies suggested reductions in rapid eye movement sleep, these were primarily based on small-scale trials with high tetrahydrocannabinol doses and significant methodological limitations.
Large Genetic Meta-Analysis Finds Endocannabinoid Pathway Variants Linked to Shared Psychiatric Risk
We identified nine SNPs significantly associated with a change in risk of having a mental disorder. The lead SNP was rs12805732 (Gene: Diacylglycerol Lipase Alpha; DAGLA). Four SNPs had substantial heterogeneity (I²>60%). DAGLA had the strongest association with disease risk in gene-based analysis.
Cannabidiol Probably Reduces Seizures in Drug-Resistant Epilepsy—But Serious Side Effects Also Rise
Cannabidiol 20 mg/kg/day and 10 mg/kg/day probably increased the frequency of participants who achieved a ≥50% reduction in monthly seizures (20 mg/kg/day: RR 1.92; 95% CI 1.49–2.46; 10 mg/kg/day: RR 1.94; 95% CI 1.32–2.86, moderate certainty). The incidence of serious adverse events is probably increased with CBD 20 mg/kg/day (RR 2.30; 95% CI 1.36–3.89, moderate certainty).
Cannabis for MS Spasticity: A Systematic Review With Critically Unreliable Pooled Estimates
Substantial heterogeneity (I² = 100% for overall and AS analyses; 91% for NRS) and asymmetry in funnel plots suggest possible publication bias and study variability.
Cannabis Does Not Consistently Change Sleep Architecture, Meta-Analysis Finds
Findings indicate that cannabis administration does not consistently alter sleep duration, latency, wake time, efficiency, or sleep staging. While early studies suggested reductions in rapid eye movement sleep, these were primarily based on small-scale trials with high tetrahydrocannabinol doses and significant methodological limitations.